Versartis, Inc. (NASDAQ:VSAR) has been given a $14.00 price objective by equities research analysts at Cantor Fitzgerald in a report released on Friday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock.

VSAR has been the subject of several other research reports. BidaskClub downgraded Versartis from a “buy” rating to a “hold” rating in a research note on Sunday, July 16th. Piper Jaffray Companies reiterated a “buy” rating and set a $26.00 price target on shares of Versartis in a research report on Friday, September 8th. Morgan Stanley reiterated an “equal weight” rating and set a $4.00 price target (up previously from $3.00) on shares of Versartis in a research report on Friday, September 22nd. Zacks Investment Research downgraded Versartis from a “hold” rating to a “sell” rating in a research report on Wednesday, August 2nd. Finally, Citigroup Inc. downgraded Versartis from a “buy” rating to a “neutral” rating and dropped their price target for the company from $23.00 to $3.00 in a research report on Monday, September 25th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $7.22.

Versartis (NASDAQ VSAR) traded down 17.39% on Friday, reaching $1.90. The company had a trading volume of 3,617,326 shares. Versartis has a 12-month low of $1.90 and a 12-month high of $24.00. The stock’s 50-day moving average price is $8.29 and its 200-day moving average price is $15.32. The stock’s market capitalization is $67.60 million.

Versartis (NASDAQ:VSAR) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported ($1.40) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.78). During the same period last year, the company posted ($0.92) earnings per share. On average, equities research analysts anticipate that Versartis will post ($3.61) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Versartis, Inc. (VSAR) PT Set at $14.00 by Cantor Fitzgerald” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/10/28/versartis-inc-vsar-pt-set-at-14-00-by-cantor-fitzgerald.html.

In related news, major shareholder Life Sciences Maste Perceptive sold 2,130,000 shares of the firm’s stock in a transaction dated Friday, September 22nd. The stock was sold at an average price of $3.29, for a total transaction of $7,007,700.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. In the last quarter, insiders have sold 2,132,769 shares of company stock valued at $7,014,761. Corporate insiders own 10.90% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. First Quadrant L P CA purchased a new position in shares of Versartis during the 2nd quarter valued at about $155,000. Bank of America Corp DE raised its holdings in shares of Versartis by 46.3% during the 1st quarter. Bank of America Corp DE now owns 9,482 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 3,001 shares in the last quarter. Tudor Investment Corp ET AL purchased a new position in shares of Versartis during the 2nd quarter valued at about $218,000. Numeric Investors LLC purchased a new position in shares of Versartis during the 2nd quarter valued at about $246,000. Finally, Voya Investment Management LLC raised its holdings in shares of Versartis by 26.1% during the 2nd quarter. Voya Investment Management LLC now owns 14,960 shares of the biopharmaceutical company’s stock valued at $261,000 after buying an additional 3,094 shares in the last quarter. 73.61% of the stock is currently owned by institutional investors.

About Versartis

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.

Analyst Recommendations for Versartis (NASDAQ:VSAR)

Receive News & Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.